Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer

Table 1 The association between the expressions of karyopherin A2 and clinicopathology of patients with triple-negative breast cancer, n (%)

Clinical data	Cases	KPNA2 positive expression rate	χ2	P value
Age (yr)			2.868	0.090
< 50	55	33 (60.00)
≥ 50	63	47 (74.60)
BMI (kg/m2)			0.271	0.602
< 22	60	42 (70.00)
≥ 22	58	38 (65.52)
Karnofsky score (points)			0.088	0.767
< 70	52	36 (69.23)
≥ 70	66	44 (66.67)
Differentiation degree			0.393	0.531
High differentiation	51	33 (64.71)
Medium low differentiation	67	47 (70.15)
Intravascular tumor thrombus			8.511	0.004
Yes	25	23 (92.00)
No	93	57 (61.29)
Tumor size			0.136	0.712
> 5 cm	53	35 (66.04)
≤ 5 cm	65	45 (69.23)
TNM stages			7.863	0.005
III	94	58 (61.70)
IV	24	22 (91.67)
Pathological type			0.301	0.583
Invasive ductal carcinoma	96	64 (66.67)
Other	22	16 (72.73)
Ki-67			2.764	0.096
≤ 14%	37	29 (78.38)
> 14%	81	51 (62.96)
P53			0.034	0.854
Positive	79	54 (68.35)
Negative	39	26 (66.67)

KPNA2: Karyopherin A2; BMI: Body mass index; TNM: Tumor-node-metastasis.